Received Jun 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 49M2F | — |
Priorix Diluent administered to patient alone (without powder); Priorix Diluent administered to patient alone (without powder); Inappropriate age at vaccine administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate preparation of medication in a 49-year-old male patient who received MMR (Priorix) (batch number 49M2F, expiry date 01-DEC-2026) for prophylaxis. On 17-MAY-2025, the patient received Priorix. On 17-MAY-2025, an unknown time after receiving Priorix, the patient experienced inappropriate preparation of medication (Verbatim: Priorix Diluent administered to patient alone (without powder)), inappropriate dose of vaccine administered (Verbatim: Priorix Diluent administered to patient alone (without powder)) and inappropriate age at vaccine administration (Verbatim: Inappropriate age at vaccine administration). The outcome of the inappropriate preparation of medication, inappropriate dose of vaccine administered and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 09-JUN-2025 Pharmacist called to inquire when to re-administer Priorix if two patients (male and a female) received only the diluent part of the vaccine, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The patient received a dose of Priorix at an inappropriate age, which led to inappropriate age at vaccine administration. The vaccine administration facility was the same as primary reporter. Permission to storage personal information within medical information database was declined. The case was linked with case US2025071740, reported by the same reporter.; Sender's Comments: US-GSK-US2025071740:same reporter